Barecetamab is under clinical development by ISU ABXIS and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Barecetamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Barecetamab overview

Barecetamab (ISU-104) is under development for the treatment of refractory solid tumors such as breast, lung, colorectal, pancreatic, and head and neck cancers. The drug candidate is administered through intravenous route. It acts by targeting the receptor tyrosine protein kinase ErbB3 (HER3) which is a member of epidermal growth factor receptor (EGFR/ERBB) family of receptor tyrosine kinases (RTK).

ISU ABXIS overview

ISU ABXIS, a subsidiary of ISU Chemical Co Ltd is a biotechnology company that discovers and develops diagnostic products and therapeutic antibodies. The company’s products include fabagal, abcertin, and clotinab. It offers clinical labs, in vitro diagnostics, chemotherapy response assay, genetic testing and tissue microarray programs, among others. ISU ABXIS also provides research and development programs for encompassing novel antigen screening, lead development and manufacturing process. The company’s antibodies are used for the treatment of heart diseases, mechanism disorders, enzyme treatment, cancer patients, autoimmune and inflammatory diseases, among others. ISU ABXIS is headquartered in Seongnam, South Korea.

For a complete picture of Barecetamab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.